MedTrace Logo

Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)

NCT01884597 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-10-09

Study results available
· View outcomes & findings →

Summary

This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.

Conditions

  • PCV
  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

high-dose ranibizumab

20mg ranibizumab vials, 0.05ml injected intravitreally, monthly

DRUG

ranibizumab

3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Hawaii Pacific Health

    lead OTHER

Principal Investigators

  • Gregg T Kokame, MD, MMM · Hawaii Pacific Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01884597 on ClinicalTrials.gov